NCT03899077 - Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP | Biotech Hunter

Enrollment

202

Participants

Timeline

Start Date

April 5, 2019

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions

Cancer of Prostate

Interventions

DRUG

Apalutamide

Apalutamide 240mg daily for 6 months (i.e. 6 28-day cycles); oral use

DRUG

Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial

Leuprorelin acetate 45mg for 6 months; subcutaneous use

DRUG

Goserelin Acetate 10.8 MG Subcutaneous Implant

Goserelin acetate 10.8mg for 6 months; subcutaneous use

DRUG

Triptorelin Pamoate

Triptorelin pamoate 22.5mg for 6 months; intramuscular use

DRUG

Degarelix acetate

Degarelix acetate 80mg for 6 months; subcutaneous use

Trial Locations (9)

1070

RECRUITING

Hopital Erasme, Brussels

1090

ACTIVE_NOT_RECRUITING

UZ Brussel, Jette

5000

ACTIVE_NOT_RECRUITING

CHU UCL Namur, Namur

7100

ACTIVE_NOT_RECRUITING

CH Jolimont, Haine-Saint-Paul

8000

RECRUITING

AZ Sint-Jan, Bruges

8500

RECRUITING

AZ Groeninge, Kortrijk

9000

RECRUITING

UZ Gent, Ghent

9300

RECRUITING

OLVZ Aalst, Aalst

Unknown

RECRUITING

GZA, Wilrijk